Invesco Nasdaq Biotechnology ETF
Key Statistics
Historical Performance
Total return including reinvested distributions, from adjusted closing prices.
Price History
Price history is being compiled for this fund.
Top Holdings
Top 25 holdings as of Feb 28, 2026 · source: SEC N-PORT. Full holdings & prospectus →
About IBBQ
The Fund generally will invest at least 90% of its total assets in the securities that comprise the Underlying Index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq, Inc. (“Nasdaq” or the “Index Provider”) compiles the Underlying Index, which is a modified market-capitalization weighted index that is designed to measure the performance of securities of companies listed on the Nasdaq Stock Market that are classified under the biotechnology subsector or pharmaceuticals subsector of the Industry Classification Benchmark (“ICB”). The Underlying Index may include securities of large-, mid- and small-capitalization companies.The Underlying Index is rebalanced annually in December and reweighted quarterly, effective at market open of the following trading day after the close of trading on the third Friday in March, June, September and December. The Fund is rebalanced and reweighted in accordance with the Underlying Index. Securities in the Underlying Index are weighted by market capitalization. At each quarter, Nasdaq reweights the Underlying Index such that the maximum weight of any constituent does not exceed 8% of the weight of the Underlying Index. Only the five largest securities may exceed a 4% cap; the individual weight of all other remaining constituents may not exceed 4% of the weight of the Underlying Index. As of October 31, 2024, the Underlying Index was comprised of 213 constituents with market capitalizations ranging from approximately $16.7 million to $220.6 billion. The Fund employs a “full replication” methodology in seeking to track the Underlying Index, meaning that the Fund generally invests in all of the securities comprising the Underlying Index in proportion to their weightings in the Underlying Index. The Fund is “non-diversified” and therefore is not required to meet certain diversification requirements under the Investment Company Act of 1940, as amended (the “1940 Act”).Concentration Policy. The Fund will concentrate its investments (i.e., invest more than 25% of the value of its net assets) in securities of issuers in the biotechnology or pharmaceutical industries that are contained in the Underlying Index. As of August 31, 2024, the Fund had significant exposure to the biotechnology industry. The Fund's portfolio holdings, and the extent to which it concentrates its investments, are likely to change over time.
IBBQ News
- Which Is the Better Invesco Healthcare ETF: Equal-Weight RSPH or Biotech-Focused IBBQ?
- Which Is the Better Invesco Healthcare ETF: Equal-Weight RSPH or Biotech-Focused IBBQ?
- Why (IBBQ) Price Action Is Critical for Tactical Trading
- XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
- XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
- Understanding Momentum Shifts in (IBBQ)
- Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ
- Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ
- Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026?
- Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026?
- Avoiding Lag: Real-Time Signals in (IBBQ) Movement
- IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?
Data for IBBQ is aggregated from third-party providers (Tiingo, Nasdaq, Finnhub) and SEC filings, may be delayed at least 20 minutes, and may be incomplete or contain errors. Nothing here is investment advice. Verify with the official prospectus before investing.